Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult‐onset Still’s disease receiving interleukin‐6 inhibitor treatment
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.14371
Abstract: Macrophage activation syndrome (MAS), a severe complication of systemic adult‐onset Still’s disease (AOSD), has been reported to occur during interleukin‐6 (IL‐6) inhibitor treatment. However, predictors for MAS development are unknown. Therefore, this study investigated predictive… read more here.
Keywords: macrophage activation; inhibitor treatment; activation syndrome; inhibitor ... See more keywords